I guess it depends on what YC is trying to do. You have to remember a lot of investors shy away from biotech due to the huge capital investments that need to be made for new drugs or devices.
What I've noticed with the latest YC biotech start-ups is they tend to be much more focused on ideas that don't require a huge amount of capital (diagnostic platforms, biofuels, etc).
Comments
I guess it depends on what YC is trying to do. You have to remember a lot of investors shy away from biotech due to the huge capital investments that need to be made for new drugs or devices.
What I've noticed with the latest YC biotech start-ups is they tend to be much more focused on ideas that don't require a huge amount of capital (diagnostic platforms, biofuels, etc).
There is actually investment into the area of minimizing capital requirements.